SCHEMBL2420264

SCHEMBL2420264

CC(C)OC(=Cc1ccccc1)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=Cc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.36
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
ALDH1A1 P00352 2/20 0.33
AKR1C3 P42330 1/20 0.33
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
MAPT P10636 1/20 0.31
NR1I2 O75469 1/20 0.30
LMNA P02545 1/20 0.30
PRNP P04156 1/20 0.30
FBP1 P09467 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27841375 0.84 MEN1 (0.37) TSHRMEN1KMT2AALDH1A1AKR1C3
SCHEMBL22335 0.84 MEN1 (0.37) TSHRMEN1KMT2AALDH1A1AKR1C3
SCHEMBL4168927 0.81 ALDH1A1 (0.40) TSHRALDH1A1AKR1C3CYP2C9FBP1
SCHEMBL4160807 0.81 ALDH1A1 (0.40) TSHRALDH1A1AKR1C3CYP2C9FBP1
SCHEMBL23444 0.81 ALDH1A1 (0.40) TSHRALDH1A1AKR1C3CYP2C9FBP1
SCHEMBL23069335 0.81 ALDH1A1 (0.40) TSHRALDH1A1AKR1C3CYP2C9FBP1
SCHEMBL27841652 0.81 ALDH1A1 (0.40) TSHRALDH1A1AKR1C3CYP2C9FBP1
SCHEMBL27778800 0.81 FBP1 (0.32) TSHRMEN1KMT2AALDH1A1AKR1C3
SCHEMBL2418975 0.81 ALDH1A1 (0.41) TSHRMEN1KMT2AALDH1A1AKR1C3
SCHEMBL23364 0.80 MEN1 (0.47) TSHRMEN1KMT2AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9604992-B2 Compounds of dibenzylidene sorbitol ester type, process of preparation, use, compositions comprising them and cosmetic treatment method L'OREAL (FR) 2017-03-28 US disclosed
US-20130039862-A1 COMPOUNDS OF DIBENZYLIDENE SORBITOL ESTER TYPE, PROCESS OF PREPARATION, USE, COMPOSITIONS COMPRISING THEM AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2013-02-14 US disclosed
EP-2542556-A1 COMPOUNDS OF DIBENZYLIDENE SORBITOL ESTER TYPE, PROCESS OF PREPARATION, USE, COMPOSITIONS COMPRISING THEM AND COSMETIC TREATMENT METHOD L'Oréal (FR) 2013-01-09 EP disclosed
WO-2011107403-A1 COMPOUNDS OF DIBENZYLIDENE SORBITOL ESTER TYPE, PROCESS OF PREPARATION, USE, COMPOSITIONS COMPRISING THEM AND COSMETIC TREATMENT METHOD L'OREAL (FR) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130039862-A1 COMPOUNDS OF DIBENZYLIDENE SORBITOL ESTER TYPE, PROCESS OF PREPARATION, USE, COMPOSITIONS COMPRISING THEM AND COSMETIC TREATMENT METHOD C1R, SORD, C1S TSHR 1195/4885MEN1 1965/4885KMT2A 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.